Redefining the Possibilities for Patients With HER2-Positive Gastroesophageal Cancers

Learn how expert faculty are optimizing testing for and treatment of HER2-positive gastroesophageal cancers with this on-demand webcast and downloadable slideset from a live roundtable, along with a focused expert commentary.

Share

Program Content

Activities

HER2 Positive Gastroesophageal Cancers
Redefining the Possibilities for Patients With HER2-Positive Gastroesophageal Cancers
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2024

Expires: June 02, 2025

Activities

Gastroesophageal Cancers at ASCO 2024
Redefining the Possibilities for Patients With HER2-positive Gastroesophageal Cancers
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2024

Expires: June 12, 2025

Activities

HER2 Positive Gastroesophageal Cancers FAQ
Expert Answers to FAQs on Management of HER2-Positive Gastroesophageal Cancers
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 02, 2024

Expires: July 01, 2025

Faculty

cover img faculity

Jaffer Ajani, MD

Professor 
Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Nataliya Uboha, MD, PhD

Faculty Leader for Early Phase Oncology Therapeutics Program
Associate Professor, Department of Medicine
Section of Hematology & Oncology
University of Wisconsin
Madison, Wisconsin

cover img faculity

Zev A. Wainberg, MD

Professor of Medicine and Surgery
Co-Director, GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca